Despite these promising findings, hepato-cancerogenic effects of HGF/c-Met and Keap1/Nrf2 activity currently limit the therapeutic exploitation of the potential beneficial properties of HGF/c-Met and NRF2 in human NASH. The gene discussed is KEAP1; the disease is metabolic dysfunction-associated steatohepatitis.